Relmada Therapeutics, Inc.
RLMD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001553643
In the last 90 days, Relmada Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $693.7M in total; no superinvestor holds it.
Holders of 5% or more of RLMD
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Relmada Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Squadron Capital Management LLC | 13G/A | 9.90%3.30M shares | +3.70 ppfrom 6.20% | May 1, 20252 filings | Aug 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Relmada Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 20256:28 PM ET | Ikarian Capital, LLCand 1 other | 13G | 4.80%3.54M shares | NewBelow 5% | Sep 30, 2025 | SEC |
| Aug 14, 20255:22 PM ET | Squadron Capital Management LLCand 2 others | 13G/A | 9.90%3.30M shares | +3.70 ppfrom 6.20% | Jun 30, 2025 | SEC |
| May 1, 20254:21 PM ET | Squadron Capital Management LLCand 2 others | 13G | 6.20%2.05M shares | New | Apr 24, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Relmada Therapeutics, Inc. shares.
No Form 144 notices for Relmada Therapeutics, Inc. are on file.